Could SER-109 be an Answer for Recurrent C.Difficile Infection?
from Evidence Based Medicine presented by InpharmD™
A phase 3, double-blind, randomized, placebo-controlled trial conducted to show superiority of SER-109 in reducing the risk of C. difficile infection recurrence up to 8 weeks after treatment.
Embed this episode
No transcript yet.
Frequently asked questions
How long is this episode of Evidence Based Medicine presented by InpharmD™?
This episode is 5 minutes long.
When was this Evidence Based Medicine presented by InpharmD™ episode published?
This episode was published on February 22, 2022.
Can I download this Evidence Based Medicine presented by InpharmD™ episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.